Corvus Pharmaceuticals shares surged after the company reported positive results from cohort 4 of its atopic dermatitis trial. The study showed strong safety and efficacy, with 75% of treated patients achieving EASI 75 and consistent outcomes versus earlier cohorts, boosting investor optimism.